MR
MRVI.US Maravai Lifesciences Holdings Inc
- Market cap
- USD 1.96B
- P/E
- -
- P/B
- 5.75x
- ROE
- -20.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MRVI.US undervalued?
Graham numberThe Graham number of Maravai Lifesciences Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Maravai Lifesciences Holdings Inc fundamental analysis
No fundamental analysis for Maravai Lifesciences Holdings Inc yet.
Maravai Lifesciences Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonu…
Full company profileMaravai Lifesciences Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Maravai Lifesciences Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 124M | 143M | 284M | 799M | 883M | 289M | 259M | 186M | 218M |
| Gross Profit | 63.1M | 76.3M | 204M | 659M | 714M | 140M | 108M | 33.4M | 94.1M |
| Operating Income | 16.4M | 24.0M | 120M | 555M | 574M | -31.6M | -236M | -6.74M | -44.3M |
| EBITDA | 33.2M | 48.2M | 138M | 586M | 610M | 712M | -157M | -148M | 1.02M |
| Net Income | -17.7M | -8.49M | 76.9M | 182M | 220M | -119M | -145M | -131M | -40.0M |
| EPS | -0.20 | -0.09 | 0.80 | 1.49 | 1.67 | -0.90 | -1.05 | -0.90 | -0.27 |
| Balance Sheet | |||||||||
| Total Assets | 540M | 578M | 1.27B | 1.92B | 2.28B | 1.49B | 1.01B | 771M | 600M |
| Total Liabilities | 392M | 433M | 1.12B | 1.37B | 1.38B | 698M | 431M | 398M | 260M |
| Shareholders' Equity | 144M | 141M | 88.5M | 315M | 545M | 417M | 325M | 212M | 196M |
| Cash & Short-term Investments | 21.9M | 24.7M | 236M | 551M | 632M | 575M | 322M | 217M | 73.0M |
| Total Debt | 340M | 390M | 591M | 575M | 585M | 611M | 377M | 35.6M | 226M |
| Cash Flow | |||||||||
| Operating Cash Flow | -186K | 24.1M | 152M | 369M | 536M | 126M | 7.47M | -57.6M | 23.6M |
| Capital Expenditure | 3.61M | 17.1M | 25.4M | 14.9M | 17.1M | 65.6M | 29.7M | 13.1M | 7.11M |
| Free Cash Flow | -3.80M | 6.97M | 127M | 354M | 519M | 60.7M | -22.2M | -70.7M | 16.5M |
| Ratios | |||||||||
| ROE | -12.3% | -6.0% | 86.9% | 57.7% | 40.4% | -28.6% | -44.5% | -61.6% | -20.4% |
| ROA | -3.3% | -1.5% | 6.1% | 9.5% | 9.6% | -8.0% | -14.4% | -17.0% | -6.7% |
| Net Profit Margin | -14.3% | -5.9% | 27.1% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% | -18.4% |
| Debt to Equity | 2.35x | 2.76x | 6.67x | 1.82x | 1.07x | 1.47x | 1.16x | 0.17x | 1.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Maravai Lifesciences Holdings Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 153M | 1.26 | 84.3% |
| 2020 | USD 609M | 6.30 | 792.5% |
| 2019 | USD 97.1M | 1.00 | - |
| 2018 | USD 52.1M | 0.59 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Maravai Lifesciences Holdings Inc
- Insiders 7.46%
- Institutions 92.54%
- Public & others 0.00%
- Shares outstanding 149M
- Free float 107M
Top funds holding MRVI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.71M | 2.48% | 0.00% | Sep 2026 |
| First Eagle Small Cap Opportunity I | 2.88M | 1.93% | -5.53% | Sep 2026 |
| iShares Russell 2000 ETF | 2.85M | 1.91% | 0.00% | Oct 2026 |
| Fidelity Small Cap Growth | 2.33M | 1.56% | +84.51% | Aug 2026 |
| Columbia Small Cap Growth Inst | 1.82M | 1.22% | +17.58% | Sep 2026 |
| Fidelity Capital Appreciation | 1.69M | 1.13% | +110.64% | Sep 2026 |
| Nuveen Quant Small Cap Equity R6 | 1.62M | 1.09% | +1.62% | Sep 2026 |
| Meridian Contrarian Legacy | 1.33M | 0.89% | +3.92% | Sep 2026 |
| Fidelity Small Cap Index | 1.23M | 0.83% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 1.22M | 0.82% | +84.94% | Aug 2026 |
| Royce Micro-Cap Trust | 1.08M | 0.73% | -4.79% | Sep 2026 |
| iShares Russell 2000 Value ETF | 1.07M | 0.72% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 980K | 0.66% | -15.13% | Sep 2026 |
| Columbia Acorn Inst | 940K | 0.63% | +51.95% | Sep 2026 |
| Federated Hermes MDT Small Cap Core IS | 925K | 0.62% | 0.00% | Sep 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 897K | 0.60% | +0.43% | Oct 2026 |
| Alger Small Cap Focus I | 889K | 0.60% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 864K | 0.58% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 677K | 0.45% | +0.24% | Oct 2026 |
| Vanguard Russell 2000 ETF | 656K | 0.44% | +1.25% | Sep 2026 |
Top institutions holding MRVI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| GTCR LLC | 20.2M | 13.50% | 0.00% | Jun 2026 |
| BlackRock Inc | 9.97M | 6.68% | +6.69% | Jun 2026 |
| BRAIDWELL LP | 8.70M | 5.83% | -15.01% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 7.34M | 4.92% | +190.87% | Jun 2026 |
| 12 West Capital Management LP | 7.06M | 4.73% | -2.75% | Jun 2026 |
| Millennium Management LLC | 6.51M | 4.36% | +294.56% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.28M | 3.54% | -3.05% | Jun 2026 |
| Ophir Asset Management Pty Ltd | 4.83M | 3.23% | 0.00% | Jun 2026 |
| Deutsche Bank AG | 4.30M | 2.88% | +401.59% | Jun 2026 |
| Renaissance Technologies Corp | 3.99M | 2.67% | -13.43% | Sep 2026 |
| Geode Capital Management, LLC | 3.13M | 2.10% | +10.66% | Jun 2026 |
| State Street Corp | 2.90M | 1.94% | +19.47% | Jun 2026 |
| Nuveen, LLC | 2.86M | 1.91% | +1,141.63% | Jun 2026 |
| JPMorgan Chase & Co | 2.59M | 1.74% | +625.96% | Jun 2026 |
| Two Sigma Investments LLC | 2.26M | 1.51% | +42.79% | Jun 2026 |
| Monaco Asset Management | 2.23M | 1.49% | -34.78% | Jun 2026 |
| Prudential Financial Inc | 2.15M | 1.44% | +11,552.16% | Jun 2026 |
| Citadel Advisors Llc | 2.12M | 1.42% | +43.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.01M | 1.34% | -37.43% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.91M | 1.28% | -42.51% | Jun 2026 |
Maravai Lifesciences Holdings Inc company profile
- Company name
- Maravai Lifesciences Holdings Inc
- Ticker
- MRVI.US
- Exchange
- USA Stocks
- Listed since
- Nov 20, 2020
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 410
- Fiscal year end
- December
- Address
- 10770 Wateridge Circle, San Diego, CA, United States, 92121
- Phone
- 858 546 0004
- Website
- maravai.com
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Maravai Lifesciences Holdings Inc management
10- Mr. Robert Andrew Eckert M.B.A.Chairman of the Board · born 1962
- Mr. Bernd BrustCEO & Director · born 1967
- Mr. Rajesh J. AsorpotaEVP & Chief Financial Officer · born 1967
- Mr. Kurt A. Oreshack J.D.Executive VP, General Counsel & Secretary · born 1981
- Ms. Christine DolanExecutive VP & GM of Cygnus Technologies · born 1968
- Ms. Chanfeng ZhaoSenior VP & Chief Scientific Officer
- Ms. Debra HartSenior Director of Investor Relations
- Ms. Judith A. SoleckiSenior VP & Chief Human Resources Officer
- Dr. Kate E. Broderick Ph.D.Executive Vice President
- Mr. Christopher C. BenoitExecutive VP & Advisor